Michael J. Morin, PhD
President and Chief Executive Officer
Mike Morin, PhD, President and Chief Executive Officer, has had a productive career in cancer research, with a long-standing commitment to improving patient care. As Vice President in Pfizer Global R&D, he led Antibacterials, Immunology and Cancer drug discovery in Groton, CT. During his extensive Pfizer career, Mike had oversight for the discovery of approximately 40 clinical candidates, many of which are progressing in active development. Most notable among those activities was his direct leadership in the discovery through Phase 2 proof-of-concept for erlotinib (TarcevaTM), a small molecule inhibitor of the epidermal growth factor receptor tyrosine kinase (a blockbuster drug marketed by Roche and Astellas). Additional candidates from his teams, both monoclonal antibodies and small molecules, have also achieved full development status and are moving through late-stage clinical trials and NDA filings. Since 2008, Mike worked as an advisor and as a C-level interim leader of venture-backed biotechnology companies, including Supportive Therapeutics (CEO) and Onkaido (CSO). Mike remains a committed supporter of academic cancer programs at the local and national levels, and he continues to contribute to the peer-review process within the cancer research community. This includes many years of service as co-chair of the NCI Experimental Therapeutics (NExT) review panel, chair of the Drug Discovery Initiative of the Children’s Tumor Foundation, and the Scientific Advisory Boards of the Ontario Institute of Cancer Research and of the Terri Brodeur Breast Cancer Foundation. Mike also serves as an executive advisor for the sciences and new ventures at UMass Lowell, where he is also an adjunct professor in the Kennedy College of Sciences. Mike received his baccalaureate in Biological Sciences from UMass Lowell and his PhD in Cancer Pharmacology from SUNY Buffalo (Roswell Park Graduate Division). He was an NIH postdoctoral fellow with Professor Alan Sartorelli at the Yale Comprehensive Cancer Center.
Scott Dessain, MD, PhD
Chief Technology Officer
Scott Dessain, MD, PhD, is the co-founder and Chief Technology Officer (CTO) of Immunome and is an Associate Professor at the Lankenau Institute for Medical Research. He received MD and PhD degrees from Yale University in 1994. He pursued post-graduate medical training in Internal Medicine at Brigham and Women’s Hospital, followed by a fellowship in Medical Oncology at Dana Farber/Partners Cancer Care Boston, MA. His post-doctoral training was with Dr. Robert Weinberg at the Whitehead Institute in Cambridge, MA, at which time he devised novel techniques to efficiently clone native human antibodies. Following his fellowship, Scott spent two years as an instructor at the Massachusetts General Hospital in Boston, specializing in bone marrow transplantation and malignant hematology and then joined the faculty of the Cardeza Foundation for Hematologic Research at the Thomas Jefferson University in Philadelphia. He has contributed to dozens of published scientific articles and multiple patents. Scott has received K08 and R01 research grants from the National Institute of Health. He is Board-Certified in Medical Oncology and attends at the Lankenau Hospital.
Matthew K. Robinson, PhD
Vice President, R&D
Matt Robinson, PhD, Vice President of R&D, has 15 years of experience in the antibody engineering field. Previously, he was on the faculty at the Fox Chase Cancer Center where he led a research laboratory developing antibody-based molecules for the detection and treatment of cancer. Matt was a co-founder of RAbD Biotech, a company focused on the computational design of antibodies. He has also served on the Scientific Advisory Boards of a number of antibody-focused biotechnology companies, including Viventia Bio (now Eleven Bio), Avipep Pty. Ltd. and Oncobiologics. He is on the steering committee for the American Association for Pharmaceutical Sciences Pharmaco-Imaging Focus Group and has served on multiple NIH, DoD and American Cancer Society study sections. He earned a BS degree in biology from Allegheny College and PhD in genetics from the University of Rochester School of Medicine. He then performed post-doctoral work at Yale University School of Medicine before joining Fox Chase Cancer Center.
Lauren A. Pitt, PhD
As Director of R&D, Lauren Pitt, PhD, is responsible for leading Immunome’s high-throughput screening and target identification platforms. Most recently, Lauren served as post-doctoral researcher at the Skirball Institute at the New York University School of Medicine, where she investigated the role of homing receptors in the survival and maintenance of T cell acute lymphoblastic leukemia. Her work highlighted the importance of the receptor CXCR4 in this disease and was published in Cancer Cell in 2015. Lauren earned her BS/BA degrees at Monash University in Australia and was awarded BS Honors the following year at The University of Melbourne. She remained at The University of Melbourne to complete her PhD in Immunology, supported by a Pre-Doctoral Emphasis Pathway in Tumor Immunology Scholarship awarded by the Cancer Research Institute.
Donna Henry, MS, PMP
Senior Director, Operations
Donna Henry, Senior Director of Operations, has more than 20 years of development, regulatory and operational experience in the biopharmaceutical industry. Prior to joining Immunome, she was Senior Director of Clinical Development at Marinus Pharmaceuticals. She has managed neuroscience, oncology, osteoporosis, infectious disease and immunology programs in all phases of development for biotechnology and pharmaceutical companies including Locus Pharmaceuticals, Azelon Pharmaceuticals and OPKO. She began her career at Merck Research Laboratories in Worldwide Regulatory Affairs. After several years, she transitioned into Global R&D Project Management where she managed the late-stage development as well as the US, EU and worldwide regulatory filing and approval of EMEND (aprepitant) for chemotherapy-induced nausea and vomiting program. Upon promotion to Director of Research Integration, Donna was responsible for managing the MRL early drug development portfolio and leading process improvement initiatives within the R&D organization.
Interim Chief Financial Officer
David Kutcher serves as Immunome’s interim Chief Financial Officer. He is also a principal and co-founder of Broadband Capital Partners and the VP of Corporate Development for Committed Capital Acquisition Corporation II, a publicly listed acquisition vehicle. Prior to Broadband Capital Partners, David was a Managing Director at Broadband Capital Management LLC, a New York based investment and merchant bank, where he was focused on principal investment opportunities for the firm. He received a BA degree from the University of the South and a JD degree from Samford University.